Trial Profile

A Phase 2b study of MYMD-1 in sarcopenia/frailty

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Mar 2025 According to TNF Pharmaceuticals media release, data for a phase 2a study presented at 15th International Conference on Frailty and Sarcopenia Research (ICFSR), showcases the rationale for current Phase 2b study in elderly sarcopenia patients and the optimal oral dosing regimen going forward.
25 Feb 2025 Status changed from planning to recruiting as per TNF Pharmaceuticals media release
25 Feb 2025 According to TNF Pharmaceuticals media release, the sites principal investigator is Porter Young, M.D., an assistant professor of orthopaedic surgery and rehabilitation at the University of Florida.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com